Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieAnimalsHumansMesothelinCell LineTumor
Development of recombinant Mesozumab-CPTin that dual-targets mesothelin and CP2c for anticancer therapy.
Boram Kim, Kyu Tae Byun, Junmin Cho, Inbeom Lee, DongSun Park, Tae-Bong Kang, Hyung-Sik Won, So Yeong Cheon, Chan Gil Kim
Published: 202510.1016/j.biopha.2025.118799
Abstract
Current pharmacotherapeutics using antibody-drug conjugates (ADCs) for cancer therapy present limitations, such as off-target effects and safety concerns. To address them, we have developed CPTin, a cell-penetrating, cancer cell-specific cytotoxic pe…
Preview only. Read the full abstract at the source